Close

Bicycle Therapeutics (BCYC) PT Lowered to $75 at Needham & Company on Toxicity Limitations, But Reiterates Competitiveness and Differentiation of BT8009

April 12, 2022 6:08 AM EDT Send to a Friend
Needham & Company analyst Ami Fadia lowered the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $75.00 (from $85.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login